Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

about

Transcription Factor Retinoid-Related Orphan Receptor γt: A Promising Target for the Treatment of Psoriasis.

P2860

Q55031102-2DE2CA19-6C15-41E2-9233-3C94E15A3BE9

P2860

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

Item

http://www.wikidata.org/entity/Q55101112

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

@en

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

@nl

type

Item

label

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

@en

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

@nl

prefLabel

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

@en

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

@nl

P1476

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

@en

P2093

Caleb Jeon

http://www.w3.org/2001/XMLSchema#string

Di Yan

http://www.w3.org/2001/XMLSchema#string

Ethan Levin

http://www.w3.org/2001/XMLSchema#string

Ladan Afifi

http://www.w3.org/2001/XMLSchema#string

Mio Nakamura

http://www.w3.org/2001/XMLSchema#string

Tina Bhutani

http://www.w3.org/2001/XMLSchema#string

P2860

The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings

Structure and signalling in the IL-17 receptor family

Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials

Immunology of psoriasis

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

IL-17 family cytokines and the expanding diversity of effector T cell lineages

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)

The IL-23/Th17 axis in the immunopathogenesis of psoriasis.

Role of IL-17 in psoriasis and psoriatic arthritis.

P304

65-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/PTT.S129792

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sahil Sekhon

P577

2017-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29387609

http://www.w3.org/2001/XMLSchema#string

P932

5774608

http://www.w3.org/2001/XMLSchema#string

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

about

P2860

P2860

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932